Abstract Topics

  • Optimal treatments for newly diagnosed and relapsed patients
  • Bispecific and conjugated monoclonal antibodies
  • Chemotherapy-free treatments
  • Minimal residual disease (MRD) testing in the clinic
  • CAR T cell and CAR NK cell therapies
  • Future role of bone marrow transplant
  • New drugs in development